Relapsed/Refractory CLL/SLL and MCL: Training and Resources to Optimize Outcomes

Download slides, watch a webcast, and read a commentary featuring expert perspectives on advances in BTK inhibitor treatment for relapsed/refractory CLL and MCL.

Share

Program Content

Activities

Call to Action: R/R CLL and MCL
Call to Action: Addressing Barriers to Optimal Management of Patients With Relapsed/Refractory CLL and MCL Using Innovative Therapies
Clinical Thought
Congratulations: You achieved a completion on 04/09/2022

Released: September 13, 2023

Expires: September 12, 2024

Activities

Treating R/R CLL/SLL and MCL
Optimizing Outcomes for Relapsed/Refractory CLL/SLL and MCL
Slideset
Congratulations: You achieved a completion on 04/09/2022

Released: October 30, 2023

Expires: October 29, 2024

Activities

Optimizing Outcomes in R/R Blood Cancers
Relapsed/Refractory CLL/SLL and MCL: Training and Resources to Optimize Outcomes
Video
Congratulations: You achieved a completion on 04/09/2022

Released: December 14, 2023

Expires: December 13, 2024

Faculty

cover img faculity

Farrukh T Awan, MD, MS, MBA

Professor of Internal Medicine
Director of Lymphoid Malignancies Program
Harold C. Simmons Comprehensive Cancer Center
University of Texas Southwestern Medical Center
Dallas, Texas

cover img faculity

Kami Maddocks, MD

Professor-Clinical, Division of Hematology
Director, Lymphoma Program
Associate Division Director for Ambulatory Operations, Division of Hematology
Medical Director, Infusion Services
Associate Chief Medical Officer, The James Cancer Hospital
Chief of Staff – Elect, The James Cancer Hospital
The Ohio State University Comprehensive Cancer Center
Arthur G. James Cancer Hospital and Richard J. Solove Research Institute
Columbus, Ohio

cover img faculity

Jennifer A. Woyach, MD

D. Warren Brown Professor of Leukemia Research
Division of Hematology
The Ohio State University
Columbus, Ohio

Provided by

ProCE Banner

Provided by Clinical Care Options, LLC

Supporters

This activity is supported by an educational grant from Lilly.

Lilly